InflaRx (IFRX) EBIT Growth (3y) (2019 - 2026)
InflaRx (IFRX) EBIT Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 6.70% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 8.36% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 69.02% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 24.14% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 44.54% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 44.34% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 81.27% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -18.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -28.30% |
| 10 | InflaRx | 135.25 Mn | -49.00 Mn | 2.74 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8,953.53% |
| Dec 31, 2025 | 93.51% |
| Sep 30, 2025 | -8.54% |
| Jun 30, 2025 | -132.76% |
| Mar 31, 2025 | 6.39% |
| Dec 31, 2024 | 72.22% |
| Sep 30, 2024 | -3.96% |
| Jun 30, 2024 | 0.51% |
| Mar 31, 2024 | -12.38% |
| Dec 31, 2023 | -35.10% |
| Sep 30, 2023 | 98.83% |
| Jun 30, 2023 | -0.55% |
| Mar 31, 2023 | 98.98% |
| Dec 31, 2022 | -25.99% |
| Sep 30, 2022 | 99.21% |
| Jun 30, 2022 | 60.08% |
| Mar 31, 2022 | -10.29% |
| Dec 31, 2021 | -36.11% |
| Sep 30, 2021 | -15.24% |
| Jun 30, 2021 | -20.08% |